Connecting Healthcare - Healthcare Communications Network

Peer-influenced content. Sources you trust. No registration required. This is HCN.

Essential Medical Reading

Your Weekly Roundup of the Most-Read News and Clinical References from Your Peers

A Practical Approach to Selecting Patients for Amyloid-Targeting Treatments

A clinician review outlined how diagnostic confidence, staging, genetic risk, and imaging features inform patient selection for amyloid-targeting Alzheimer’s therapies.

Neurology May 28th 2026

Tags: ALZHEIMER'S/DEMENTIA BIOMARKERS DISEASE-MODIFYING THERAPIES (DMTs) MEDICAL OPINION/COMMENTARY NEUROIMAGING SHARED DECISION-MAKING

Epilepsy Currents

Beyond the First Pill and the First Year: Rethinking Treatment Response in Newly Diagnosed Focal Epilepsy

Most newly diagnosed focal epilepsy patients required more than a year and more than one antiseizure medication to reach seizure freedom in a multicenter cohort.

Neurology May 28th 2026

Tags: ANTISEIZURE MEDICATIONS COMORBIDITIES DRUG EFFICACY EPILEPSY/SEIZURES MEDICAL OPINION/COMMENTARY RISK STRATIFICATION

Huntington’s Disease News

First Huntington’s Patient Dosed in Large Trial of Oral Therapy Votoplam

The first participant was dosed in a Phase 3 trial of oral votoplam, as interim Phase 2 extension data suggested dose-dependent slowing of Huntington’s progression.

Neurology May 28th 2026

Tags: BIOMARKERS DRUG PIPELINE GENETIC DISORDERS HUNTINGTON'S DISEASE MOVEMENT DISORDERS PERSONALIZED MEDICINE RESEARCH & CLINICAL TRIALS

Medical Professionals Reference (MPR)

Asundexian Gets FDA Priority Review for Secondary Stroke Prevention

The FDA accepted asundexian’s secondary-stroke-prevention application for Priority Review, supported by phase 3 OCEANIC-STROKE results in noncardioembolic ischemic stroke.

Neurology May 28th 2026

Tags: ANTICOAGULATION MANAGEMENT ANTITHROMBOTIC THERAPY DEVICE/DRUG APPROVALS FDA RESEARCH & CLINICAL TRIALS STROKE

Neurology Advisor

Midlife Sleep-Derived Brain Health Score Predicts Future Cognition

A machine learning sleep EEG score measured in midlife was associated with neuropsychological performance over a decade later in a Framingham cohort.

Neurology May 28th 2026

Tags: ARTIFICIAL INTELLIGENCE (AI) COGNITIVE HEALTH/MEMORY COHORT STUDY INSOMNIA/SLEEP DISORDERS RISK STRATIFICATION SLEEP MEDICINE

ReachMD

Low-Dose Naltrexone in Major Depressive Disorder: Trial Findings

Adjunctive low-dose naltrexone did not separate from placebo on depressive symptom reduction in a 38-patient randomized trial of adults with moderate major depressive disorder on existing antidepressants.

Psychiatry May 27th 2026

Tags: CLINICAL STUDY DEPRESSION INFLAMMATION MOOD DISORDERS OFF-LABEL USE PHARMACOTHERAPY PSYCHOPHARMACOLOGY

1 2 … 798 799 >>

Trending Topics:

Essential Medical Reading

A Practical Approach to Selecting Patients for Amyloid-Targeting Treatments

Beyond the First Pill and the First Year: Rethinking Treatment Response in Newly Diagnosed Focal Epilepsy

First Huntington’s Patient Dosed in Large Trial of Oral Therapy Votoplam

Asundexian Gets FDA Priority Review for Secondary Stroke Prevention

Midlife Sleep-Derived Brain Health Score Predicts Future Cognition

Low-Dose Naltrexone in Major Depressive Disorder: Trial Findings

Topics

Sources

The Healthcare Communications Network is owned and operated by IQVIA Inc. Click below to leave this site and continue to IQVIA’s Privacy Choices form

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form